Watson Biologics Signs Strategic Cooperation Agreement for Overseas Markets to Accelerate the Internationalization of Chinese Vaccines

Log in to Sina Finance App and search for [Information Disclosure] to see more evaluation levels.

On March 14, 2026, Yunnan Walvax Biotechnology Co., Ltd. (hereinafter referred to as “Walvax Biotech,” stock code: 300142) announced that its wholly-owned subsidiary Walvax Hong Kong Limited (hereinafter referred to as “Hong Kong Walvax”) and Jiangsu Zhonghui Yuantong Biotechnology Co., Ltd. (hereinafter referred to as “Zhonghui Yuantong”) officially signed the “Overseas Market Strategic Cooperation Agreement.” The two parties reached a deep cooperation on the development of the overseas market for the trivalent influenza virus subunit vaccine. This move marks a further expansion of Walvax Biotech’s overseas vaccine product line and a new step in its globalization strategy.

According to the agreement, Zhonghui Yuantong designates Hong Kong Walvax (or its designated affiliates) as its exclusive international business development partner for the trivalent influenza virus subunit vaccine in global (excluding the Philippines and Macau) public and private markets. Hong Kong Walvax will be fully responsible for registration applications (including potential clinical trials), marketing, and sales of the product within the cooperation regions.

The trivalent influenza virus subunit vaccine involved in this cooperation is Zhonghui Yuantong’s core product, featuring advanced technology and broad applicable populations, aligning with global influenza vaccine market development trends. Leveraging years of experience in overseas registration systems, localized operations, and extensive commercial channels, Walvax Biotech has established a comprehensive market layout in Southeast Asia, South Asia, Central Asia, Africa, and the Americas. Securing exclusive rights to this product will create synergy with the company’s already commercialized 13-valent pneumococcal conjugate vaccine and bivalent HPV vaccine, forming a richer overseas vaccine portfolio and significantly enhancing the company’s competitiveness in the global respiratory vaccine market.

This cooperation is an important move for both parties to leverage their respective advantages and achieve resource complementarity. Zhonghui Yuantong has deep technical expertise and high-quality product reserves in influenza vaccine R&D and manufacturing, while Walvax Biotech possesses mature overseas market experience and an internationalized operational system. This will help promote domestically produced high-end influenza vaccines to a broader international market and further strengthen Walvax Biotech’s global competitiveness in the vaccine industry.

Walvax Biotech stated that this strategic cooperation is an important step in the company’s deepening internationalization, expanding product portfolio, and global deployment. Through this partnership, Walvax Biotech will further enhance its international influence in the field of influenza vaccines and accumulate valuable experience for the overseas registration and commercialization of more Chinese vaccine products in the future.

(This article does not constitute any investment advice. The information disclosed is subject to the company’s announcements. Investors operate at their own risk.)

Text by Eleven

Massive information, precise analysis, all on Sina Finance App